oric pharmaceuticals, inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. its lead product candidate is oric-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. the company's second product candidate is oric-533, an orally bioavailable small molecule inhibitor of cd73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. it is also developing multiple precision medicines targeting other cancer resistance mechanisms. the company was founded in 2014 and is headquartered in south san francisco, california.
Company profile
Ticker
ORIC
Exchange
Website
CEO
Jacob Chacko
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
471787157
ORIC stock data
Latest filings (excl ownership)
S-3ASR
Automatic shelf registration
11 Mar 24
10-K
2023 FY
Annual report
11 Mar 24
8-K
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
11 Mar 24
EFFECT
Notice of effectiveness
5 Feb 24
CORRESP
Correspondence with SEC
31 Jan 24
UPLOAD
Letter from SEC
31 Jan 24
D
$125.00 mm in equity, sold $125.00 mm, 10 investors
30 Jan 24
S-3
Shelf registration
26 Jan 24
8-K
ORIC Pharmaceuticals Announces $125 Million Private Placement Financing
22 Jan 24
8-K
Results of Operations and Financial Condition
9 Jan 24
Transcripts
Latest ownership filings
SC 13G/A
FMR LLC
11 Mar 24
4
Jacob Chacko
8 Mar 24
144
Notice of proposed sale of securities
6 Mar 24
SC 13G/A
EcoR1 Capital, LLC
14 Feb 24
SC 13G/A
ALKEON CAPITAL MANAGEMENT LLC
13 Feb 24
SC 13G/A
Prosight Management, LP
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Jacob Chacko
8 Feb 24
SC 13G/A
BlackRock Inc.
7 Feb 24
SC 13G/A
MILLENNIUM MANAGEMENT LLC
6 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 26.73 mm | 26.73 mm | 26.73 mm | 26.73 mm | 26.73 mm | 26.73 mm |
Cash burn (monthly) | 25.82 mm | 234.58 k | 9.56 mm | 8.46 mm | 6.55 mm | 6.40 mm |
Cash used (since last report) | 153.58 mm | 1.40 mm | 56.88 mm | 50.31 mm | 38.96 mm | 38.05 mm |
Cash remaining | -126.85 mm | 25.33 mm | -30.15 mm | -23.58 mm | -12.23 mm | -11.32 mm |
Runway (months of cash) | -4.9 | 108.0 | -3.2 | -2.8 | -1.9 | -1.8 |
Institutional ownership, Q3 2023
92.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 94 |
Opened positions | 16 |
Closed positions | 9 |
Increased positions | 27 |
Reduced positions | 28 |
13F shares | Current |
---|---|
Total value | 290.48 bn |
Total shares | 62.38 mm |
Total puts | 100.00 k |
Total calls | 15.00 k |
Total put/call ratio | 6.7 |
Largest owners | Shares | Value |
---|---|---|
PFE Pfizer | 5.38 mm | $31.08 mm |
Nextech Invest | 4.29 mm | $25.93 bn |
Nextech Crossover I GP S.a r.l. | 4.29 mm | $36.00 mm |
BLK Blackrock | 3.73 mm | $22.58 bn |
Column Group Ii | 3.57 mm | $52.45 mm |
Column | 3.57 mm | $21.59 bn |
Alkeon Capital Management | 3.48 mm | $21.05 bn |
EcoR1 Capital | 3.42 mm | $20.68 bn |
FMR | 3.13 mm | $18.95 bn |
Vanguard | 2.59 mm | $15.66 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Mar 24 | Chacko Jacob | Common Stock | Sell | Dispose S | No | Yes | 16.2095 | 40,000 | 648.38 k | 728,544 |
7 Feb 24 | Chacko Jacob | Common Stock | Sell | Dispose S | No | Yes | 12.295 | 26,042 | 320.19 k | 768,544 |
6 Feb 24 | Chacko Jacob | Common Stock | Sell | Dispose S | No | Yes | 12.1192 | 13,958 | 169.16 k | 794,586 |
2 Jan 24 | Chacko Jacob | RSU Common Stock | Grant | Acquire A | No | No | 0 | 85,000 | 0.00 | 85,000 |
2 Jan 24 | Chacko Jacob | Stock Option Common Stock | Grant | Acquire A | No | No | 9.14 | 510,000 | 4.66 mm | 510,000 |
2 Jan 24 | Piscitelli Dominic | RSU Common Stock | Grant | Acquire A | No | No | 0 | 30,000 | 0.00 | 30,000 |
2 Jan 24 | Piscitelli Dominic | Stock Option Common Stock | Grant | Acquire A | No | No | 9.14 | 180,000 | 1.65 mm | 180,000 |
2 Jan 24 | Multani Pratik S | RSU Common Stock | Grant | Acquire A | No | No | 0 | 30,000 | 0.00 | 30,000 |
2 Jan 24 | Multani Pratik S | Stock Option Common Stock | Grant | Acquire A | No | No | 9.14 | 180,000 | 1.65 mm | 180,000 |
News
JP Morgan Maintains Overweight on ORIC Pharmaceuticals, Lowers Price Target to $18
27 Mar 24
Micron To Rally Around 134%? Here Are 10 Top Analyst Forecasts For Thursday
21 Mar 24
HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $21
21 Mar 24
These Analysts Revise Their Forecasts On ORIC Pharmaceuticals After Q4 Results
12 Mar 24
Oppenheimer Maintains Outperform on ORIC Pharmaceuticals, Raises Price Target to $17
12 Mar 24
Press releases
ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
6 Mar 24
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
1 Mar 24
ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit
14 Feb 24
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2 Feb 24
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
31 Jan 24